AstraZeneca AB/CAMBRIA-1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence.

The purpose of this study is to see if extended therapy with the experimental drug camizestrant is better at preventing disease recurrence than continuation of the standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen) that patients with early ER+/HER2- breast cancer are currently receiving.

Learn more about the CAMBRIA-1 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.